Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy

被引：0
|
作者：
Wei Chen
Shuifang Hu
Zelong Liu
Yukun Sun
Jian Wu
Shunli Shen
Zhenwei Peng
机构：
[1] The First Affiliated Hospital of Sun Yat-Sen University,Center of Hepato
[2] The First Affiliated Hospital of Sun Yat-Sen University,Pancreato
[3] The First Affiliated Hospital of Sun Yat-Sen University, Biliary Surgery
[4] The First Affiliated Hospital of Sun Yat-Sen University,Department of Pancreaticobiliary Surgery
[5] The First Affiliated Hospital of Sun Yat-Sen University,Department of Radiation Oncology
[6] The First Affiliated Hospital of Sun Yat-Sen University,Department of Liver Surgery
[7] The First Affiliated Hospital of Sun Yat-Sen University,Institute of Precision Medicine
来源：
Hepatology International | 2023年 / 17卷
关键词：
Hepatocellular carcinoma; Hepatic venous tumor thrombus; Independent prognostic factors; Overall survival; Postoperative adjuvant therapy; Portal venous tumor thrombus; Programmed cell death 1; Propensity-score matching; Recurrence; Recurrence-free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：406 / 416
页数：10
相关论文
共 50 条
  • [1] Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy
    Chen, Wei
    Hu, Shuifang
    Liu, Zelong
    Sun, Yukun
    Wu, Jian
    Shen, Shunli
    Peng, Zhenwei
    HEPATOLOGY INTERNATIONAL, 2023, 17 (02) : 406 - 416
  • [2] Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
    Ouyang, Jingzhong
    Wang, Zhengzheng
    Yuan, Kun
    Yang, Yi
    Zhou, Yanzhao
    Li, Qingjun
    Yang, Nanmu
    Zhao, Haitao
    Zhao, Hong
    Zhou, Jinxue
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1465 - 1477
  • [3] Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis
    Li, Chenggang
    Shen, Hanchuan
    Zhang, Hangyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
    Owen, C. N.
    Shoushtari, A. N.
    Chauhan, D.
    Palmieri, D. J.
    Lee, B.
    Rohaan, M. W.
    Mangana, J.
    Atkinson, V
    Zaman, F.
    Young, A.
    Hoeller, C.
    Hersey, P.
    Dummer, R.
    Khattak, M. A.
    Millward, M.
    Patel, S. P.
    Haydon, A.
    Johnson, D. B.
    Lo, S.
    Blank, C. U.
    Sandhu, S.
    Carlino, M. S.
    Larkin, J. M. G.
    Menzies, A. M.
    Long, G., V
    ANNALS OF ONCOLOGY, 2020, 31 (08) : 1075 - 1082
  • [6] Effectiveness of anti-PD-1 for hepatocellular carcinoma
    Liao, Rui
    LANCET ONCOLOGY, 2020, 21 (06): : E293 - E293
  • [7] Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
    Xiao-Dong Zhu
    Cheng Huang
    Ying-Hao Shen
    Bin Xu
    Ning-Ling Ge
    Yuan Ji
    Xu-Dong Qu
    Lingli Chen
    Yi Chen
    Mei-Ling Li
    Jin-Jin Zhu
    Zhao-You Tang
    Jian Zhou
    Jia Fan
    Hui-Chuan Sun
    Annals of Surgical Oncology, 2023, 30 : 2782 - 2790
  • [8] Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Xu, Bin
    Ge, Ning-Ling
    Ji, Yuan
    Qu, Xu-Dong
    Chen, Lingli
    Chen, Yi
    Li, Mei-Ling
    Zhu, Jin-Jin
    Tang, Zhao-You
    Zhou, Jian
    Fan, Jia
    Sun, Hui-Chuan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 2782 - 2790
  • [9] Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy
    Xuehan Shen
    Wei Yan
    Erlei Zhang
    Zhiwei Zhang
    Zunyi Zhang
    Hanhua Dong
    European Journal of Medical Research, 30 (1)
  • [10] Effectiveness of anti-PD-1 for hepatocellular carcinoma Reply
    Qin, Shukui
    Ren, Zhenggang
    Meng, Zhiqiang
    Chen, Zhendong
    Chai, Xiaoli
    LANCET ONCOLOGY, 2020, 21 (06): : E294 - E294
12345